Biomark Capital Management
Latest statistics and disclosures from Biomark Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ADMA, Mabvax Therapeutics Holdings, and represent 100.00% of Biomark Capital Management's stock portfolio.
- Biomark Capital Management has $8.9M in assets under management (AUM), dropping by 37.59%.
- Central Index Key (CIK): 0001667082
Tip: Access up to 7 years of quarterly data
Positions held by Biomark Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Biomark Capital Management
Biomark Capital Management holds 2 positions in its portfolio as reported in the September 2018 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Adma Biologics (ADMA) | 100.0 | $8.9M | 1.4M | 6.21 |
|
|
| Mabvax Therapeutics Holdings | 0.0 | $4.0k | 8.9k | 0.45 |
|
Past Filings by Biomark Capital Management
SEC 13F filings are viewable for Biomark Capital Management going back to 2015
- Biomark Capital Management 2018 Q3 filed Oct. 24, 2018
- Biomark Capital Management 2018 Q2 filed Aug. 9, 2018
- Biomark Capital Management 2018 Q1 filed April 20, 2018
- Biomark Capital Management 2017 Q4 filed Feb. 13, 2018
- Biomark Capital Management 2017 Q3 filed Oct. 30, 2017
- Biomark Capital Management 2017 Q2 filed Aug. 8, 2017
- Biomark Capital Management 2017 Q1 filed May 11, 2017
- Biomark Capital Management 2016 Q4 filed Feb. 13, 2017
- Biomark Capital Management 2016 Q3 filed Nov. 9, 2016
- Biomark Capital Management 2016 Q2 filed Aug. 12, 2016
- Biomark Capital Management 2016 Q1 filed June 1, 2016
- Biomark Capital Management 2015 Q4 filed Feb. 16, 2016